Vise Technologies’s Autolus Therapeutics AUTL Stock Holding History

Vise Technologies’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35.1K	Buy	+18,084	New	+$34.5K	﹤0.01%	2096

Other funds holding AUTL

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return

Dumont & Blake Investment Advisors Princeton, New Jersey $398M AUM 22.72% 1-Year Est. Return

Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return

Vise Technologies's AUTL Position: Q3 2026 in Review

Vise Technologies opened a new position in Autolus Therapeutics (AUTL) in Q3 2026: 18,084 shares worth $35.1K. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings.

18 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

Vise Technologies held 18,084 shares of Autolus Therapeutics worth $35.1K as of Q3 2026.
Autolus Therapeutics was a new Vise Technologies position in Q3 2026.
Autolus Therapeutics made up ﹤0.01% of Vise Technologies's portfolio in Q3 2026, its #2096 holding.
18 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on Vise Technologies's 13F filing for Q3 2026, filed 29 Oct 2026.